Adalimumab-atto, Fourth Biosimilar Approved by the FDA

Online First - FDA Approvals, News & Updates

On September 23, 2016, the US Food and Drug Administration (FDA) approved adalimumab-atto (Amjevita; Amgen) as a biosimilar to adalimumab (Humira; AbbVie) for the treatment of several indications and inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis; psoriatic arthritis; ankylosing spondylitis; moderate-to-severe Crohn’s disease; moderate-to-severe ulcerative colitis; and moderate-to-severe plaque psoriasis.

The new biosimilar is also indicated for the treatment of moderate-to-severe polyarticular juvenile idiopathic arthritis in patients aged ≥4 years.

“This is the fourth FDA-approved biosimilar. The biosimilar pathway is still a new frontier and one that we expect will enhance access to treatment for patients with serious medical conditions,” said Janet Woodcock, MD, Director of the FDA’s Center for Drug Evaluation and Research.

As in the case of the previous 3 biosimilars, adalimumab-atto is approved as a biosimilar, not as an interchangeable agent.

The approval of adalimumab-atto is based on review of evidence from human pharmacokinetic and pharmacodynamics data, clinical immunogenicity data, and other data demonstrating the clinical safety and effectiveness of this drug, showing that adalimumab-atto is indeed biosimilar to adalimumab.

The most common expected adverse events with adalimumab-atto are infections and injection-site reactions. This biosimilar carries a boxed warning about an increased risk for serious infections, as well as a warning that lymphoma and other malignancies have been reported in children and adolescent patients who received this type of drug.  

The third biosimilar, etanercept-szzs (Erelzi; Sandoz), was approved by the FDA on August 30, 2016, as a biosimilar to etanercept (Enbrel; Novartis) for the same indications as those approved for the reference drug.

The second biosimilar to receive FDA approval was infliximab-dyyb (Inflectra; Celltrio), a biosimilar to infliximab (Remicade; Janssen). Infliximab-dyyb was approved on April 5, 2016, for the same indications as its reference drug.

Related Items
FDA Expands Indication for Kadcyla to Include the Adjuvant Treatment of HER2-Positive Early Breast Cancer
Web Exclusives published on May 14, 2019 in Breast Cancer, FDA Approvals, News & Updates, In the News
Ivosidenib Now FDA-Approved as First-Line Treatment for AML with IDH1 Mutation
Web Exclusives published on May 7, 2019 in FDA Approvals, News & Updates, In the News
Daurismo (Glasdegib) Approved, in Combination with Low-Dose Cytarabine, for Newly Diagnosed Acute Myeloid Leukemia in Older Adults or Those Unfit for Intensive Chemotherapy
Web Exclusives published on May 6, 2019 in Drug Updates, FDA Approvals, News & Updates
Talzenna (Talazoparib) New PARP Inhibitor Approved for the Treatment of HER2-Negative Advanced Breast Cancer with Germline BRCA Mutation
Web Exclusives published on May 6, 2019 in Drug Updates, FDA Approvals, News & Updates
FDA Approves Pembrolizumab plus Axitinib for Advanced Renal-Cell Carcinoma
Web Exclusives published on April 23, 2019 in FDA Approvals, News & Updates, In the News
Last modified: October 17, 2016
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME